Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Moderate Buy” by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $12.90.

CMPX has been the subject of several analyst reports. Guggenheim upped their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Wednesday, November 5th. Finally, Lifesci Capital initiated coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 price objective for the company.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Victory Capital Management Inc. boosted its position in Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after acquiring an additional 2,164 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock valued at $619,000 after purchasing an additional 3,329 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Compass Therapeutics by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock worth $463,000 after purchasing an additional 5,590 shares in the last quarter. Alps Advisors Inc. boosted its holdings in shares of Compass Therapeutics by 11.3% during the third quarter. Alps Advisors Inc. now owns 83,007 shares of the company’s stock worth $291,000 after purchasing an additional 8,410 shares during the period. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics during the third quarter worth approximately $35,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $4.90 on Thursday. The firm has a market cap of $677.57 million, a price-to-earnings ratio of -10.89 and a beta of 1.48. Compass Therapeutics has a 1 year low of $1.27 and a 1 year high of $5.05. The firm’s 50 day moving average price is $3.85 and its two-hundred day moving average price is $3.03.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.